360° SearchNetwork Hot Spots Trends Time Series

myelofibrosis

Type: Keyphrase

Name: myelofibrosis

First reported 15 hours ago - Updated 15 hours ago - 1 reports

Data from M.D. Anderson Cancer Center Advance Knowledge in Hematology

(NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Current study results on Hematology have been published. According to news reporting originating from Houston, Texas, by NewsRx correspondents, research stated, "Myelofibrosis (MF) ... [Published NewsRX - 15 hours ago]

Entities: Hematology, Ruxolitinib, myelofibrosis, SPLEEN

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Sanofi SA

Sanofi Highlights Positive PhIII Study for Myelofibrosis Contender

Fierce Biotech (05/17/13) McBride, Ryanbody: Sanofi has released some of the results from its phase III trial of SAR302503, a JAK2 inhibitor used to treat myelofibrosis. The study met its primary endpoint for the proportion of patients who experienced ... [Published AAPS Pharmceutica - May 23 2013]

Entities: myelofibrosis, Sanofi SA, Jakafi, Incyte Corporation

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Cell Therapeutics, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 02:30 PM

Unknown AnalystSo I'm [indiscernible]. I cover biotech space in Europe for UBS. I just would like to introduce Dr. Blanco, CEO for CTI. So you can have probably a 25 minutes presentation.James A. BiancoThank you. Good afternoon. As is typical of the presentations ... [Published Seeking Alpha - May 22 2013]

Entities: Patient, Ruxolitinib, SPLEEN, thrombocyte, Pixuvri

First reported May 20 2013 - Updated May 21 2013 - 1 reports

Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars - new market research report

Innovative and improved drugs therapies developed through novel target discovery and technology platforms have originated from the backyards of small research focused companies (Rising Stars, RS, non-profitable biotech companies). The universe continues ... [Published TransWorldNews - May 20 2013]

Entities: Drugs, Biotechnology, Pipeline, myelofibrosis, Anti-Obesity

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Incyte Corporation CEO Presents at UBS Global Healthcare Conference (Transcript)

Incyte Corporation (INCY) UBS Global Healthcare Conference May 20, 2013 2:30 PM ETMatt Roden - UBSGood afternoon everyone. My name is Matt Roden. I'm one of the Biotech analysts here at UBS and I'd like to thank everyone for attending the new UBS Global ... [Published Seeking Alpha - May 20 2013]

Entities: Jakafi, Patient, Incyte Corporation

First reported May 17 2013 - Updated May 17 2013 - 20 reports

Sanofi (France) (SAN.PA) Plans to File JAK2 Inhibitor After Positive Phase III

- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its primary endpoint in both dose groups. The primary endpoint assessed the proportion ... [Published BioSpace - May 17 2013]

Entities: Sanofi SA, Phase III, primary endpoint, France, myelofibrosis

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Incyte's Management Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)

Incyte Corporation (INCY) Bank of America Merrill Lynch 2013 Healthcare Conference May 15, 2013 5:20 PM ETRachel McMinnThanks for joining us. I am Rachel McMinn, the Biotech Analyst here at BOA Merrill Lynch. I appreciate you guys coming to the conference. ... [Published Seeking Alpha - May 16 2013]

Entities: Incyte Corporation, Jakafi, Baricitinib, myelofibrosis, Bank of America Merrill Lynch

First reported May 04 2013 - Updated May 04 2013 - 1 reports

Cell Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcript

4:30 PM ETOperatorGood day, ladies and gentlemen. Thank you for standing by. Welcome to the Cell Therapeutics Q1 2013 Financial Results Conference Call. [Operator Instructions] This conference is being recorded today, May 2, 2013. I would now like to ... [Published Seeking Alpha - May 04 2013]

Entities: Pixuvri, myelofibrosis, thrombocyte, Patient

First reported May 03 2013 - Updated May 03 2013 - 1 reports

George Glushenok

(1941-2013) died Wednesday morning, April 24, following a long struggle with myelofibrosis.He was born on Manhattan where his family resided until they moved to Jackson, N.J.Following graduation from Lakewood High School in 1959, George attended Rutgers ... [Published San Mateo Daily Journal - May 03 2013]

Entities: Lydia Davis, Robert Mayer, Atlanta, myelofibrosis, San Francisco (United States)

First reported May 02 2013 - Updated May 03 2013 - 2 reports

Incyte Corp. edges toward profitability with sales of Jakafi

Drug startup shows steady gains in Jakafi sales Pharmaceutical startup Incyte Corp. reported a solid first quarter Thursday linked to the success of its first major drug launched to treat a life-threatening cancer, myelofibrosis.Sales of Jakafi, a potential ... [Published Delaware Online - May 03 2013]

Entities: Jakafi, Incyte Corporation, myelofibrosis, Drugs, Novartis AG

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Cancer sufferer pleads with MP after...

A DOCTOR who suffers from a rare form of blood cancer has written to his MP after a national health watchdog said it would not recommend treatment for his condition on the NHS.For five months, Dr Colin Clayton has been on the 43,000-a-year drug ruxolitinib ... [Published Derby Telegraph - Apr 29 2013]

Entities: National Institute for Health & Clinical Excell..., NHS, Cancer, myelofibrosis

First reported Apr 26 2013 - Updated Apr 26 2013 - 1 reports

NICE publishes final draft recommendations for a new treatment for enlarged spleen in adults with a rare blood cancer.

NICE has published final draft guidance not recommending ruxolitinib (Jakavi, Novartis), for the treatment of disease-related splenomegaly (enlarged spleen) or its symptoms in adults with primary myelofibrosis, or post polycythaemia vera myelofibrosis ... [Published NICE | National Institute for Health and Clinic ... - Apr 26 2013]

Entities: SPLEEN, Blood Cancer, myelofibrosis

Quotes

...According to news reporting originating from Houston, Texas, by NewsRx correspondents, research stated, "Myelofibrosis (MF) patients can present with a wide spectrum of disease characteristics. We analysed the consistency of ruxolitinib efficacy across patient subgroups in the COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment (COMFORT-I,) a double-blind trial, where patients with intermediate-2 or high-risk MF were randomized to twice-daily oral ruxolitinib (n = 155) or placebo (n = 154)."

Data from M.D. Anderson Cancer Center Advance Knowledge in Hematology [Published NewsRX - 15 hours ago]

...which underscore the safety and potential of PRM-151 as a novel therapeutic to treat IPF, a serious and life threatening orphan fibrotic disease? "We are excited to present data from this clinical study, which underscore the safety and potential of PRM-151 as a novel therapeutic to treat IPF, a serious and life threatening orphan fibrotic disease,” said Beth Trehu, MD, FACP, Chief Medical Officer. "The safety profile and intriguing efficacy signals seen in this Phase 1b multiple dose trial of PRM-151 in patients with IPF support advancement of this clinical program to Phase 2. We are also initiating clinical development of PRM-151 in myelofibrosis, another serious and life threatening orphan fibrotic disease.”"

Promedior Presents Encouraging Results from Clinical Study of PRM-151 in Patients with Idiopathic ... [Published EON: Enhanced Online News - May 22 2013]

"You have to be very careful about the balance between healthy competition and unnecessary duplication," Giles said. "Competition for competition's sake is destructive. It involves a hesitancy to share information. I try to advise people, if they are seeking something or someone to compete with, try cancer. It's a competitor we can all agree on."

Boost in Studies for Cancer Patients [Published Northwestern University - May 21 2013]

...As used herein the term "fibrosis" is used synonymously with "aberrant healing, involving mesenchymal-fibroblast cell transformation, excessive fibroblast proliferation, activity and deposition of collagens and other extracellular matrix proteins"

Humanized C-kit antibody [Published PharmCast - May 21 2013]

More Content

sort by: Date \| Relevance
Data from M.D. Anderson Cancer Center Advance K... [Published NewsRX - 15 hours ago]
Sanofi Highlights Positive PhIII Study for Myel... [Published AAPS Pharmceutica - May 23 2013]
Celgene's Management Presents at 2013 UBS Globa... [Published Seeking Alpha - May 22 2013]
Promedior Presents Encouraging Results from Cli... [Published EON: Enhanced Online News - May 22 2013]
Cell Therapeutics, Inc. Presents at UBS Global ... [Published Seeking Alpha - May 22 2013]
Boost in Studies for Cancer Patients [Published Northwestern University - May 21 2013]
Humanized C-kit antibody [Published PharmCast - May 21 2013]
Incyte Corporation CEO Presents at UBS Global H... [Published Seeking Alpha - May 20 2013]
Global Pharmaceutical & Biotechnology Outlook 2... [Published TransWorldNews - May 20 2013]
GlaxoSmithKline plc (ADR) (GSK), Sanofi SA (ADR... [Published InsiderMonkey.com - May 20 2013]
Today's Calendar: Zooluting the military, dogs,... [Published Abilene Reporter - May 18 2013]
Sanofi (France) (SAN.PA) Plans to File JAK2 Inh... [Published BioSpace - May 17 2013]
No headline - Calendar0518_web [Published Abilene Reporter - May 17 2013]
Positive Phase III Results for Myelofibrosis Tr... [Published P&T Community - May 17 2013]
Sanofi (France) Reports Positive Topline Result... [Published BioSpace - May 17 2013]
Sanofi Reports Positive Topline Results from Pi... [Published PharmiWeb - May 17 2013]
Sanofi reports on JAK2 inhibitor in MF [Published MedNous - May 17 2013]
Sanofi Presents Promising Phase III Data for My... [Published Genetic Engineering News - May 17 2013]
Sanofi highlights positive PhIII study for myel... [Published FierceBiotech - May 17 2013]
Sanofi Reports Positive Topline Results from Pi... [Published Yahoo! Finance - May 17 2013]
Sanofi (SNY) Reports JAKARTA Met Primary Endpoi... [Published Street Insider - May 17 2013]
Sanofi Reports Positive Topline Results from Pi... [Published KEYC Television - May 17 2013]
Sanofi Reports Positive Topline Results from Pi... [Published Stockwatch - May 17 2013]
Sanofi Reports Positive Topline Results from Pi... [Published PR Newswire: General Business - May 17 2013]
Sanofi to submit JAK inhibitor for MF [Published Pharma Times - May 17 2013]
Sanofi's Abnormal Blood Cell Production Inhibit... [Published RTTNews.com - May 17 2013]
Sanofi plans to file JAK2 inhibitor after posit... [Published PMLive - May 17 2013]
Sanofi:Pivotal PhaseIII JAKARTA Study Meets Pri... [Published RTTNews.com - May 17 2013]
Sanofi Reports Positive Results on Study on Inh... [Published FOXBusiness.com - May 17 2013]
Sanofi says myelofibrosis treatment study positive [Published Reuters India - May 17 2013]

Blogs

sort by: Date \| Relevance
Incyte Earnings: Here’s Why Investors are Not H... [Published Wall St. Cheat Sheet - May 02 2013] Incyte Corporation ( NASDAQ:INCY ) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 2.70%. Markets are at 5-year ...
Geron Earnings: Everything You Must Know Now [Published Wall St. Cheat Sheet - Apr 26 2013] Geron Corporation ( NASDAQ:GERN ) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Markets are at 5-year highs! Discover ...
NICE publishes final draft recommendations for ... [Published NICE \| National Institute for Health and Clinic ... - Apr 26 2013] NICE has published final draft guidance not recommending ruxolitinib (Jakavi, Novartis), for the treatment of disease-related splenomegaly (enlarged spleen) or its symptoms in adults with primary myelofibrosis, or post polycythaemia vera myelofibrosis ...
Orphan designation: N-tert-butyl-3-[(5-methyl-2... [Published Orphan designations - Apr 09 2013]
Orphan designation: N-tert-butyl-3-[(5-methyl-2... [Published Orphan designations - Apr 09 2013]

Press Releases

sort by: Date \| Relevance
Promedior Presents Encouraging Results from Cli... [Published EON: Enhanced Online News - May 22 2013]
Sanofi Reports Positive Topline Results from Pi... [Published PR Newswire: General Business - May 17 2013]
Incyte Reports First-Quarter 2013 Financial Res... [Published Business Wire Health News - May 02 2013]
The MPN Research Foundation and LLS Partner for... [Published Financial Services - Feb 14 2013]
Incyte Reports 2012 Fourth-Quarter and Full-Yea... [Published EON Health & Medicine - Feb 14 2013]